History
In 2003, Pr J.M. François and Pr J.P. Majoral patented the dendrimer-based DNA microarrays technology for molecular diagnosis. This technology is based on the coating of phosphorus dendrimers on solid supports. This allows covalent linkages of oligonucleotide probes, which greatly optimizes DNA hybridization (i.e.10-fold higher signal than other commercial technologies). From 2003 to 2007, the proof of concept and technological readiness has been demonstrated in several publications.
In 2009, Dr R. Fabre, biologist (Bio Pôle), founding biologist of the Biopole laboratory discovers J.M. François and J.P. Majoral ’s invention. Together they decide to create a company with the aim of developing a new generation of diagnostic tools exploiting the invention of the two researchers.
The Dendris company was therefore born from the cooperation of scientists and a practicing biologist and is based on the exploitation of this surface chemistry by Dendrimers.
M. Corbarieu and A. Leonard, successful entrepreneurs joined Dendris in 2010, as business manager and member of the guidance and supervision service respectively.
Creation
2009
2015
Internal
Production
LBM Biopole partnership
Certification
ISO 13485
2017
2018
Partnership
KOL pilot sites
Clinical validation
CE Mark DCHIP RD v1
2019
2021
Development
Validation of an
automated version
TRL8
Contract of
Co-development
CE Mark
– DKIT OA
– DKIT DP
Innovative
Biotechnology
with deposit
patent
2022
2023
Commercial
Launch
March 2023: 1st commercial installation
High added value
The new generation of Dendris solutions allows laboratories to use a powerful and intelligent syndromic approach to strengthen collaboration with clinicians and protect patients at risk